Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Arthritis in Idiopathic Inflammatory Myopathies.

Klein M, Mann H, Vencovský J.

Curr Rheumatol Rep. 2019 Dec 7;21(12):70. doi: 10.1007/s11926-019-0878-x. Review.

PMID:
31813070
2.

Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.

Tužil J, Mlčoch T, Jirčíková J, Závada J, Nekvindová L, Svoboda M, Uher M, Křístková Z, Vencovský J, Pavelka K, Doležal T.

Expert Opin Biol Ther. 2020 Feb;20(2):183-192. doi: 10.1080/14712598.2020.1694900. Epub 2019 Nov 25.

PMID:
31736377
3.

Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis.

Betteridge Z, Chinoy H, Vencovsky J, Winer J, Putchakayala K, Ho P, Lundberg I, Danko K, Cooper R, McHugh N.

Rheumatology (Oxford). 2019 Sep 17. pii: kez406. doi: 10.1093/rheumatology/kez406. [Epub ahead of print]

PMID:
31728542
4.

Idiopathic Inflammatory Myopathies.

Vencovský J, Alexanderson H, Lundberg IE.

Rheum Dis Clin North Am. 2019 Nov;45(4):569-581. doi: 10.1016/j.rdc.2019.07.006. Review.

PMID:
31564297
5.

Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.

Putrik P, Ramiro S, Guillemin F, Péntek M, Sivera F, Sokka T, de Wit M, Woolf AD, Zink A, Andersone D, Berghea F, Butrimiene I, Brouwer S, Cassar K, Charalambous P, Caporali R, Deseatnicova E, Damjanov NS, Finckh A, FitzGerald O, Gröndal G, Gobejishjvili N, Gluszko P, Hirsch M, Jovanovic I, Vencovský J, Janssens X, Keszei AP, Kovarova M, Kull M, Cunha Miranda L, Mayer M, Misevska-Percinkova S, Inanc N, Nadashkevich O, Petersson IF, Puolakka K, Rojkovich B, Radner H, Szabados F, Slobodin G, Shirinsky I, Soroka N, Sidiropoulos P, Shumnalieva R, Sokolovic S, Shukurova S, Tafaj A, Tomšič M, Uhlig T, Verstappen SMM, Boonen A.

Ann Rheum Dis. 2019 Nov;78(11):1472-1479. doi: 10.1136/annrheumdis-2019-215294. Epub 2019 Aug 19.

PMID:
31427438
6.

Patients with rheumatoid arthritis acquire sustainable skills for home monitoring: a prospective dual-country cohort study (ELECTOR clinical trial I).

Skougaard M, Bliddal H, Christensen R, Ellegaard K, Nielsen SM, Zavada J, Oreska S, Krogh NS, Holm CC, Hetland ML, Vencovsky J, Røgind H, Taylor PC, Gudbergsen H.

J Rheumatol. 2019 Aug 15. pii: jrheum.181362. doi: 10.3899/jrheum.181362. [Epub ahead of print]

PMID:
31416921
7.

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovský J, Deakin CT, Dankó K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen PR, Radstake TRDJ, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE; Myositis Genetics Consortium (MYOGEN).

Ann Rheum Dis. 2019 Jul;78(7):996-1002. doi: 10.1136/annrheumdis-2019-215046. Epub 2019 May 28.

8.

Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.

Hulejová H, Kropáčková T, Bubová K, Kryštůfková O, Filková M, Mann H, Forejtová Š, Tomčík M, Vencovský J, Pavelka K, Šenolt L.

Rheumatol Int. 2019 Jun;39(6):1037-1043. doi: 10.1007/s00296-019-04301-z. Epub 2019 Apr 25.

PMID:
31025138
10.

Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.

Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N; UKMyonet contributors.

J Autoimmun. 2019 Jul;101:48-55. doi: 10.1016/j.jaut.2019.04.001. Epub 2019 Apr 13.

11.
12.

S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals.

Cerezo LA, Šumová B, Hulejová H, Štorkánová H, Szczuková L, Tomčík M, Bečvář R, Pavelka K, Vencovský J, Závada J, Šenolt L.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):338-339. Epub 2019 Feb 4. No abstract available.

13.

Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis.

Andrés Cerezo L, Hulejová H, Šumová B, Kropáčková T, Kryštůfková O, Klein M, Mann HF, Zámečník J, Pecha O, Pavelka K, Vencovský J, Šenolt L.

Cytokine. 2019 Apr;116:13-20. doi: 10.1016/j.cyto.2018.12.023. Epub 2019 Jan 23.

PMID:
30684913
14.

Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.

Mann HF, Závada J, Šenolt L, Bubová K, Nekvindová L, Křístková Z, Horák P, Vencovský J, Pavelka K; and the ATTRA Registry.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):342-343. Epub 2019 Jan 4. No abstract available.

15.

Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis.

Tang Q, Ramsköld D, Krystufkova O, Mann HF, Wick C, Dastmalchi M, Lakshmikanth T, Chen Y, Mikes J, Alexanderson H, Achour A, Brodin P, Vencovsky J, Lundberg IE, Malmström V.

Scand J Immunol. 2019 Jan;89(1):e12732. doi: 10.1111/sji.12732. Epub 2018 Dec 9.

16.

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.

Šumová B, Cerezo LA, Szczuková L, Nekvindová L, Uher M, Hulejová H, Moravcová R, Grigorian M, Pavelka K, Vencovský J, Šenolt L, Závada J.

Rheumatol Int. 2019 Mar;39(3):469-478. doi: 10.1007/s00296-018-4190-2. Epub 2018 Nov 3.

PMID:
30392117
17.

The role of imaging in evaluating patients with idiopathic inflammatory myopathies.

Kubínová K, Dejthevaporn R, Mann H, Machado PM, Vencovský J.

Clin Exp Rheumatol. 2018 Sep-Oct;36 Suppl 114(5):74-81. Epub 2018 Oct 1. Review.

18.

Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis.

Kryštůfková O, Hulejová H, Mann HF, Pecha O, Půtová I, Ekholm L, Lundberg IE, Vencovský J.

Arthritis Res Ther. 2018 Jul 27;20(1):158. doi: 10.1186/s13075-018-1650-8.

19.

Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain.

Kropáčková T, Šléglová O, Růžičková O, Vencovský J, Pavelka K, Šenolt L.

BMC Musculoskelet Disord. 2018 Jul 27;19(1):264. doi: 10.1186/s12891-018-2179-3.

20.

Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.

Hurnakova J, Hulejova H, Zavada J, Komarc M, Cerezo LA, Mann H, Vencovsky J, Pavelka K, Senolt L.

Clin Rheumatol. 2018 Aug;37(8):2055-2062. doi: 10.1007/s10067-018-4091-5. Epub 2018 Apr 14.

PMID:
29656372
21.

[Idiopathic inflammatory myopathies].

Vencovský J.

Vnitr Lek. Spring 2018;64(2):155-163. Czech.

PMID:
29595280
22.

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M.

Arthritis Rheumatol. 2018 May;70(5):679-689. doi: 10.1002/art.40420. Epub 2018 Mar 31.

23.

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.

van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team.

Ann Rheum Dis. 2018 Apr;77(4):495-499. doi: 10.1136/annrheumdis-2017-212478. Epub 2018 Jan 17.

PMID:
29343509
24.

Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis.

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovský J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K.

Ann Rheum Dis. 2018 Apr;77(4):602-611. doi: 10.1136/annrheumdis-2017-212149. Epub 2018 Jan 13.

PMID:
29331962
25.

Response to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna et al.

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Jordan P, Benveniste O, Danieli MG, Dankó K, Phuong Thuy NT, Vázquez-Del Mercado M, Andersson H, Paepe B, De Bleecker JL, Maurer B, McCann LJ, Pipitone N, McHugh N, Betteridge Z, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H; all EuroMyositis contributors.

Ann Rheum Dis. 2018 Aug;77(8):e51. doi: 10.1136/annrheumdis-2017-212382. Epub 2017 Dec 19. No abstract available.

PMID:
29259048
26.

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.

Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) .

RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.

27.

2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland).

Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum in: Arthritis Rheumatol. 2018 Sep;70(9):1532.

28.

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland).

Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27. Erratum in: Ann Rheum Dis. 2018 Sep;77(9):e64.

29.

Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.

Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studýnková J, Chura R, Gullick NJ, Salerno R, Rönnelid J, Alexanderson H, Lindroos E, Aggarwal R, Gordon P, Vencovsky J, Lundberg IE.

Ann Rheum Dis. 2018 Jan;77(1):55-62. doi: 10.1136/annrheumdis-2017-211751. Epub 2017 Oct 9.

PMID:
28993346
30.

2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.

Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, García-De la Torre I, Reed AM, Wook Song Y, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J, Aggarwal R; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Rheumatology (Oxford). 2017 Nov 1;56(11):1884-1893. doi: 10.1093/rheumatology/kex226.

31.

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.

Emery P, Vencovský J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J.

Rheumatology (Oxford). 2017 Dec 1;56(12):2093-2101. doi: 10.1093/rheumatology/kex269.

32.

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.

Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR.

Arthritis Rheumatol. 2018 Jan;70(1):49-59. doi: 10.1002/art.40323.

33.

Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis.

Prajzlerová K, Grobelná K, Hušáková M, Forejtová Š, Jüngel A, Gay S, Vencovský J, Pavelka K, Šenolt L, Filková M.

PLoS One. 2017 Sep 22;12(9):e0185323. doi: 10.1371/journal.pone.0185323. eCollection 2017.

34.

Opportunities and challenges in rheumatology research in Central Europe.

Szekanecz Z, Anic B, Héjj G, Holc I, Hunka A, Kucharz E, Machold K, Mayer M, Pahor A, Puchner R, Rovensky J, Senolt L, Tuchynova A, Vencovsky J, Smolen JS.

Arthritis Res Ther. 2017 Sep 4;19(1):196. doi: 10.1186/s13075-017-1368-z.

35.

The EuroMyositis registry: an international collaborative tool to facilitate myositis research.

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, Thuy NTP, Vazquez-Del Mercado M, Andersson H, De Paepe B, deBleecker JL, Maurer B, McCann LJ, Pipitone N, McHugh N, Betteridge ZE, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H; all EuroMyositis contributors.

Ann Rheum Dis. 2018 Jan;77(1):30-39. doi: 10.1136/annrheumdis-2017-211868. Epub 2017 Aug 30.

36.

Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.

Hurnakova J, Hulejova H, Zavada J, Hanova P, Komarc M, Mann H, Klein M, Sleglova O, Olejarova M, Forejtova S, Ruzickova O, Vencovsky J, Pavelka K, Senolt L.

PLoS One. 2017 Aug 23;12(8):e0183420. doi: 10.1371/journal.pone.0183420. eCollection 2017.

37.

MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies.

Kubínová K, Mann H, Vencovský J.

Curr Opin Rheumatol. 2017 Nov;29(6):623-631. doi: 10.1097/BOR.0000000000000435. Review.

PMID:
28796007
38.

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.

Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Stasiuk B, Hilt J, Mosterova Z, Cheong SY, Ghil J.

Ann Rheum Dis. 2017 Aug 9. pii: annrheumdis-2017-211591. doi: 10.1136/annrheumdis-2017-211591. [Epub ahead of print]

39.

Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis.

Šenolt L, Prajzlerová K, Hulejová H, Šumová B, Filková M, Veigl D, Pavelka K, Vencovský J.

Cytokine. 2017 Sep;97:187-192. doi: 10.1016/j.cyto.2017.06.009. Epub 2017 Jun 26.

PMID:
28662439
40.

Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.

Andrés Cerezo L, Šumová B, Prajzlerová K, Veigl D, Damgaard D, Nielsen CH, Pavelka K, Vencovský J, Šenolt L.

Arthritis Res Ther. 2017 Apr 26;19(1):79. doi: 10.1186/s13075-017-1288-y.

41.

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Ann Rheum Dis. 2017 May;76(5):792-801. doi: 10.1136/annrheumdis-2017-211400.

42.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Ann Rheum Dis. 2017 May;76(5):782-791. doi: 10.1136/annrheumdis-2017-211401. Erratum in: Ann Rheum Dis. 2018 Apr;77(4):623.

43.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Rheumatol. 2017 May;69(5):898-910. doi: 10.1002/art.40064. Epub 2017 Apr 6.

44.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Rheumatol. 2017 May;69(5):911-923. doi: 10.1002/art.40060. Epub 2017 Apr 6. Erratum in: Arthritis Rheumatol. 2018 Mar;70(3):467.

45.

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.

Fleischmann R, van Vollenhoven RF, Vencovský J, Alten R, Davies O, Mountian I, de Longueville M, Carter D, Choy E.

Rheumatol Ther. 2017 Jun;4(1):57-69. doi: 10.1007/s40744-017-0060-8. Epub 2017 Mar 28.

46.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

47.

International collaboration including patients is essential to develop new therapies for patients with myositis.

Lundberg IE, Vencovsky J.

Curr Opin Rheumatol. 2017 May;29(3):234-240. doi: 10.1097/BOR.0000000000000384. Review.

PMID:
28207492
48.

Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum.

Rothwell S, Cooper RG, Lundberg IE, Gregersen PK, Hanna MG, Machado PM, Herbert MK, Pruijn GJM, Lilleker JB, Roberts M, Bowes J, Seldin MF, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Platt H, Molberg Ø, Benveniste O, Radstake TRDJ, Doria A, De Bleecker J, De Paepe B, Gieger C, Meitinger T, Winkelmann J, Amos CI, Ollier WE, Padyukov L, Lee AT, Lamb JA, Chinoy H; Myositis Genetics Consortium.

Arthritis Rheumatol. 2017 May;69(5):1090-1099. doi: 10.1002/art.40045. Epub 2017 Apr 4.

49.

Molecular markers of systemic autoimmune disorders: the expression of MHC-located HSP70 genes is significantly associated with autoimmunity development.

Mišunová M, Svitálková T, Pleštilová L, Kryštufková O, Tegzová D, Svobodová R, Hušáková M, Tomčík M, Bečvář R, Závada J, Mann H, Kolesár L, Slavčev A, Vencovský J, Novota P.

Clin Exp Rheumatol. 2017 Jan-Feb;35(1):33-42. Epub 2016 Dec 28.

PMID:
28032847
50.

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, Fonseca JE, Hetland ML, Humby F, Kvien TK, Niedermann K, Nuño L, Oliver S, Rantapää-Dahlqvist S, Raza K, van Schaardenburg D, Schett G, De Smet L, Szücs G, Vencovský J, Wiland P, de Wit M, Landewé RL, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Mar;76(3):491-496. doi: 10.1136/annrheumdis-2016-209846. Epub 2016 Oct 6.

PMID:
27991858

Supplemental Content

Loading ...
Support Center